📊 BQST Key Takeaways
Investment Thesis
Bioquest Corp exhibits severe financial distress with negative stockholders' equity of -$536.4K, indicating the company is technically insolvent. Revenue generation is minimal at $31K while operating losses reach -$49.7K, demonstrating the company cannot sustain operations. Critically low liquidity (0.03x current ratio) combined with negative operating and free cash flows (-$29K) suggests imminent operational collapse.
BQST Strengths
- Minimal long-term debt burden (N/A long-term debt)
BQST Risks
- Negative stockholders' equity of -$536.4K indicating technical insolvency
- Severe liquidity crisis with current ratio of 0.03x and negative quick ratio
- Unsustainable operations with negative operating margin of -160.4% and net margin of -398.5%
- Cash burn rate exceeds revenue generation by 10x with operating cash flow of -$18.6K
- Minimal revenue base of only $31K suggests inability to support operations
- Deteriorating net income trending worse year-over-year (+64.7% loss increase)
- Zero insider transactions in past 90 days indicating potential abandonment
- Stale data from July 2022 raises concerns about current company status
Key Metrics to Watch
- Stockholders' equity recovery trajectory
- Cash position sustainability and burn rate
- Operating revenue growth and path to positive margins
- Total liabilities reduction progress
- Operating cash flow improvement and cash runway remaining
BQST Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BQST Profitability Ratios
BQST vs Healthcare Sector
How Bioquest Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BQST Balance Sheet & Liquidity
BQST 5-Year Financial Trend
5-Year Trend Summary: Bioquest Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.28 indicates the company is currently unprofitable.
BQST Growth Metrics (YoY)
BQST Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2015 | N/A | $286 | N/A |
| Q2 2015 | N/A | -$3.3K | N/A |
| Q1 2015 | N/A | -$5.0K | N/A |
| Q3 2014 | N/A | $286 | N/A |
| Q2 2014 | N/A | -$3.3K | N/A |
| Q1 2014 | N/A | -$259 | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BQST Capital Allocation
BQST SEC Filings
Access official SEC EDGAR filings for Bioquest Corp (CIK: 0001568628)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BQST
What is the AI rating for BQST?
Bioquest Corp (BQST) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BQST's key strengths?
Minimal long-term debt burden (N/A long-term debt).
What are the risks of investing in BQST?
Negative stockholders' equity of -$536.4K indicating technical insolvency. Severe liquidity crisis with current ratio of 0.03x and negative quick ratio.
What is BQST's revenue and growth?
Bioquest Corp reported revenue of $31.0K.
Does BQST pay dividends?
Bioquest Corp does not currently pay dividends.
Where can I find BQST SEC filings?
Official SEC filings for Bioquest Corp (CIK: 0001568628) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BQST's EPS?
Bioquest Corp has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.